 Home > Biochemistry News > Biotechnology News > Junshi/Lilly's new crown neutralizing antibody cocktail therapy resumes distribution in the United States

Junshi/Lilly's new crown neutralizing antibody cocktail therapy resumes distribution in the United States

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

united states satellite

united states pharmacopeia

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 27, Eli Lilly announced that the FDA has resumed the distribution of the antibody cocktail therapy bamlanivimab/etesevimab, which it has cooperated with Junshi
.

New Crown Neutralizing Antibody, which is cooperating with Junshi, brought Eli Lilly in revenue of US$871 million in 2020, and will continue to grow in Q1 of 2021, achieving US$810 million in revenue
.

Due to the impact of the new crown mutant, on June 25, 2021, the U.
S.
Department of Health and Services (HHS) announced that it would stop distributing Eli Lilly/Junshi’s new crown neutralizing antibody cocktail therapy because in vitro analysis tests showed that Lilly/Jun The neutralizing antibody has no neutralizing activity against the Brazilian mutant (P.
1) and the South African mutant (B.
1.
351), which directly affects the subsequent sales of Eli Lilly's new crown neutralizing antibody
.

Q2 Its sales dropped significantly, with revenue of only US$149 million

However, due to the pandemic of the Delta mutant strain, Eli Lilly/Junshi's new crown neutralizing antibody cocktail therapy is effective for the mutant strain
.

The resumption of distribution is expected to restore sales of the neutralizing antibody combination therapy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.